Prostate Cancer Vaccines: Progress, Challenges, and Future Directions

Authors

  • Stefanus Vicky Bernhard Elisa Runtunuwu Faculty of Medicine Student, Sam Ratulangi University, Manado 95115, Indonesia
  • Trina Ekawati Tallei Department of Biology, Faculty of Medicine, Sam Ratulangi University, Manado 95115, Indonesia; Department of Biology, Faculty of Mathematics and Natural Sciences, Sam Ratulangi University, Manado 95115, Indonesia
  • Grace Lendawati Amelia Turalaki Department of Biology, Faculty of Medicine, Sam Ratulangi University, Manado 95115, Indonesia

DOI:

https://doi.org/10.60084/hjas.v3i1.263

Keywords:

Prostate cancer, Cancer vaccines, Immunotherapy, Tumor antigens, Immunotherapy advancements

Abstract

Prostate cancer remains a major contributor to cancer-related deaths in men, with its incidence rising significantly with age. Conventional treatment modalities, including surgery, radiation therapy, hormonal therapy, and chemotherapy, often face limitations such as treatment resistance, disease recurrence, and considerable side effects. These challenges have sparked growing interest in novel approaches like immunotherapy, which leverages the immune system to combat cancer. Among these, vaccine-based immunotherapy has emerged as a promising strategy, aiming to generate precise immune responses against tumor-specific antigens. Advances in immunology, molecular targeting, and vaccine development have demonstrated encouraging results in terms of safety and immunogenicity. Nevertheless, obstacles such as tumor heterogeneity, immune escape mechanisms, and limited efficacy in advanced stages of the disease continue to hinder progress. The aim of this review is to examine the current landscape of prostate cancer vaccine development, with a focus on advancements in molecular target identification, optimization of vaccine technologies, and the evaluation of combination therapy strategies. Findings from clinical trials have shed light on both the opportunities and challenges of vaccine-based therapies. Synergistic approaches involving immune checkpoint inhibitors, radiotherapy, and androgen deprivation therapy have shown potential to amplify immune responses and mitigate resistance mechanisms. Additionally, emerging technologies such as bioinformatics and artificial intelligence are revolutionizing vaccine development by enabling the discovery of patient-specific neoantigens and the creation of tailored vaccine formulations. Despite these breakthroughs, achieving consistent therapeutic outcomes remains challenging, particularly in metastatic and castration-resistant cases. Future directions in the field include developing personalized cancer vaccines, adopting adaptive clinical trial designs, and employing innovative endpoints to streamline translation into clinical practice. In summary, while prostate cancer vaccine development has advanced significantly, addressing critical barriers like tumor heterogeneity and immune evasion and embracing emerging technologies are essential for optimizing personalized vaccines and improving treatment outcomes.

Downloads

Download data is not yet available.

References

  1. Bray, F., Laversanne, M., Sung, H., Ferlay, J., Siegel, R. L., Soerjomataram, I., and Jemal, A. (2024). Global Cancer Statistics 2022: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries, CA: A Cancer Journal for Clinicians, Vol. 74, No. 3, 229–263. doi:10.3322/caac.21834.
  2. Siegel, R. L., Miller, K. D., and Jemal, A. (2020). Cancer Statistics, 2020, CA: A Cancer Journal for Clinicians, Vol. 70, No. 1, 7–30. doi:10.3322/caac.21590.
  3. Mattiuzzi, C., and Lippi, G. (2019). Current Cancer Epidemiology:, Journal of Epidemiology and Global Health, Vol. 9, No. 4, 217. doi:10.2991/jegh.k.191008.001.
  4. Zlotta, A. R., Egawa, S., Pushkar, D., Govorov, A., Kimura, T., Kido, M., Takahashi, H., Kuk, C., Kovylina, M., Aldaoud, N., Fleshner, N., Finelli, A., Klotz, L., Sykes, J., Lockwood, G., and van der Kwast, T. H. (2013). Prevalence of Prostate Cancer on Autopsy: Cross-Sectional Study on Unscreened Caucasian and Asian Men, Journal of the National Cancer Institute, Vol. 105, No. 14, 1050–1058. doi:10.1093/jnci/djt151.
  5. Pernar, C. H., Ebot, E. M., Wilson, K. M., and Mucci, L. A. (2018). The Epidemiology of Prostate Cancer, Cold Spring Harbor Perspectives in Medicine, Vol. 8, No. 12, a030361. doi:10.1101/cshperspect.a030361.
  6. Zhang, W., Cao, G., Wu, F., Wang, Y., Liu, Z., Hu, H., and Xu, K. (2023). Global Burden of Prostate Cancer and Association with Socioeconomic Status, 1990–2019: A Systematic Analysis from the Global Burden of Disease Study, Journal of Epidemiology and Global Health, Vol. 13, No. 3, 407–421. doi:10.1007/s44197-023-00103-6.
  7. Taylor, L. G., Canfield, S. E., and Du, X. L. (2009). Review of Major Adverse Effects of Androgen‐deprivation Therapy in Men with Prostate Cancer, Cancer, Vol. 115, No. 11, 2388–2399. doi:10.1002/cncr.24283.
  8. Nagireddy, S., Qureshi, R., Best, J., Frech, F. S., Shah, K., Soni, Y., Kuchakulla, M., Narasimman, M., and Arora, H. (2021). Current Treatment Modalities Targeting Tumor Microenvironment in Castration-Resistant Prostate Cancer, A. Birbrair (Ed.), Tumor Microenvironment (Vol. 1329), Springer International Publishing, Cham, 295–323. doi:10.1007/978-3-030-73119-9_16.
  9. Karantanos, T., Corn, P. G., and Thompson, T. C. (2013). Prostate Cancer Progression after Androgen Deprivation Therapy: Mechanisms of Castrate Resistance and Novel Therapeutic Approaches, Oncogene, Vol. 32, No. 49, 5501–5511. doi:10.1038/onc.2013.206.
  10. Challa, A. A., Calaway, A. C., Cullen, J., Garcia, J., Desai, N., Weintraub, N. L., Deswal, A., Kutty, S., Vallakati, A., Addison, D., Baliga, R., Campbell, C. M., and Guha, A. (2021). Cardiovascular Toxicities of Androgen Deprivation Therapy, Current Treatment Options in Oncology, Vol. 22, No. 6, 47. doi:10.1007/s11864-021-00846-z.
  11. Bagrodia, A., DiBlasio, C. J., Wake, R. W., and Derweesh, I. H. (2009). Adverse Effects of Androgen Deprivation Therapy in Prostate Cancer: Current Management Issues, Indian Journal of Urology : IJU : Journal of the Urological Society of India, Vol. 25, No. 2, 169–176. doi:10.4103/0970-1591.52907.
  12. Nguyen, P. L., Alibhai, S. M. H., Basaria, S., D’Amico, A. V., Kantoff, P. W., Keating, N. L., Penson, D. F., Rosario, D. J., Tombal, B., and Smith, M. R. (2015). Adverse Effects of Androgen Deprivation Therapy and Strategies to Mitigate Them, European Urology, Vol. 67, No. 5, 825–836. doi:10.1016/j.eururo.2014.07.010.
  13. Belli, C., Trapani, D., Viale, G., D’Amico, P., Duso, B. A., Della Vigna, P., Orsi, F., and Curigliano, G. (2018). Targeting the Microenvironment in Solid Tumors, Cancer Treatment Reviews, Vol. 65, 22–32. doi:10.1016/j.ctrv.2018.02.004.
  14. Li, D., Xu, W., Chang, Y., Xiao, Y., He, Y., and Ren, S. (2023). Advances in Landscape and Related Therapeutic Targets of the Prostate Tumor Microenvironment, Acta Biochimica et Biophysica Sinica, Vol. 55, No. 6, 956–973. doi:10.3724/abbs.2023092.
  15. Ge, R., Wang, Z., and Cheng, L. (2022). Tumor Microenvironment Heterogeneity an Important Mediator of Prostate Cancer Progression and Therapeutic Resistance, Npj Precision Oncology, Vol. 6, No. 1, 1–8. doi:10.1038/s41698-022-00272-w.
  16. Wu, J., Ji, H., Li, T., Guo, H., Xu, H., Zhu, J., Tian, J., Gao, M., Wang, X., and Zhang, A. (2024). Targeting the Prostate Tumor Microenvironment by Plant-Derived Natural Products, Cellular Signalling, Vol. 115, 111011. doi:10.1016/j.cellsig.2023.111011.
  17. Rosenberg, S. A. (2014). IL-2: The First Effective Immunotherapy for Human Cancer, The Journal of Immunology, Vol. 192, No. 12, 5451–5458. doi:10.4049/jimmunol.1490019.
  18. Riley, R. S., June, C. H., Langer, R., and Mitchell, M. J. (2019). Delivery Technologies for Cancer Immunotherapy, Nature Reviews Drug Discovery, Vol. 18, No. 3, 175–196. doi:10.1038/s41573-018-0006-z.
  19. Kciuk, M., Yahya, E. B., Mohamed Ibrahim Mohamed, M., Rashid, S., Iqbal, M. O., Kontek, R., Abdulsamad, M. A., and Allaq, A. A. (2023). Recent Advances in Molecular Mechanisms of Cancer Immunotherapy, Cancers, Vol. 15, No. 10, 2721. doi:10.3390/cancers15102721.
  20. Kaczmarek, M., Poznańska, J., Fechner, F., Michalska, N., Paszkowska, S., Napierała, A., and Mackiewicz, A. (2023). Cancer Vaccine Therapeutics: Limitations and Effectiveness—A Literature Review, Cells, Vol. 12, No. 17, 2159. doi:10.3390/cells12172159.
  21. Donninger, H., Li, C., Eaton, J. W., and Yaddanapudi, K. (2021). Cancer Vaccines: Promising Therapeutics or an Unattainable Dream, Vaccines, Vol. 9, No. 6, 668. doi:10.3390/vaccines9060668.
  22. Kong, H. Y., and Byun, J. (2013). Emerging Roles of Human Prostatic Acid Phosphatase, Biomolecules & Therapeutics, Vol. 21, No. 1, 10–20. doi:10.4062/biomolther.2012.095.
  23. Kissick, H. T., Sanda, M. G., Dunn, L. K., and Arredouani, M. S. (2013). Development of a Peptide-Based Vaccine Targeting TMPRSS2:ERG Fusion-Positive Prostate Cancer, Cancer Immunology, Immunotherapy, Vol. 62, No. 12, 1831–1840. doi:10.1007/s00262-013-1482-y.
  24. Stultz, J., and Fong, L. (2021). How to Turn up the Heat on the Cold Immune Microenvironment of Metastatic Prostate Cancer, Prostate Cancer and Prostatic Diseases, Vol. 24, No. 3, 697–717. doi:10.1038/s41391-021-00340-5.
  25. Qi, Y., Zhang, L., Liu, Y., Li, Y., Liu, Y., and Zhang, Z. (2024). Targeted Modulation of Myeloid-Derived Suppressor Cells in the Tumor Microenvironment: Implications for Cancer Therapy, Biomedicine & Pharmacotherapy, Vol. 180, 117590. doi:10.1016/j.biopha.2024.117590.
  26. Murray, T. B. J. (2021). The Pathogenesis of Prostate Cancer, Prostate Cancer [Internet], Exon Publications. doi:10.36255/exonpublications.prostatecancer.pathogenesis.2021.
  27. Huang, L., LaBonte, M. J., Craig, S. G., Finn, S. P., and Allott, E. H. (2022). Inflammation and Prostate Cancer: A Multidisciplinary Approach to Identifying Opportunities for Treatment and Prevention, Cancers, Vol. 14, No. 6, 1367. doi:10.3390/cancers14061367.
  28. Grivennikov, S. I., Greten, F. R., and Karin, M. (2010). Immunity, Inflammation, and Cancer, Cell, Vol. 140, No. 6, 883–899. doi:10.1016/j.cell.2010.01.025.
  29. Lin, M., Sun, X., and Lv, L. (2023). New Insights and Options into the Mechanisms and Effects of Combined Targeted Therapy and Immunotherapy in Prostate Cancer, Molecular Therapy Oncolytics, Vol. 29, 91–106. doi:10.1016/j.omto.2023.04.007.
  30. de Bono, J. S., Guo, C., Gurel, B., De Marzo, A. M., Sfanos, K. S., Mani, R. S., Gil, J., Drake, C. G., and Alimonti, A. (2020). Prostate Carcinogenesis: Inflammatory Storms, Nature Reviews Cancer, Vol. 20, No. 8, 455–469. doi:10.1038/s41568-020-0267-9.
  31. Sacdalan, D. B., and Lucero, J. A. (2021). The Association Between Inflammation and Immunosuppression: Implications for ICI Biomarker Development, OncoTargets and Therapy, Vol. 14, 2053–2064. doi:10.2147/OTT.S278089.
  32. Nigam, M., Mishra, A. P., Deb, V. K., Dimri, D. B., Tiwari, V., Bungau, S. G., Bungau, A. F., and Radu, A.-F. (2023). Evaluation of the Association of Chronic Inflammation and Cancer: Insights and Implications, Biomedicine & Pharmacotherapy, Vol. 164, 115015. doi:10.1016/j.biopha.2023.115015.
  33. Wang, D., and DuBois, R. N. (2015). Immunosuppression Associated with Chronic Inflammation in the Tumor Microenvironment, Carcinogenesis, Vol. 36, No. 10, 1085–1093. doi:10.1093/carcin/bgv123.
  34. Lu, H., Ouyang, W., and Huang, C. (2006). Inflammation, a Key Event in Cancer Development, Molecular Cancer Research, Vol. 4, No. 4, 221–233. doi:10.1158/1541-7786.MCR-05-0261.
  35. Lin, R., Zhang, C., Zheng, J., Tian, D., Lei, Z., Chen, D., Xu, Z., and Su, M. (2016). Chronic Inflammation-Associated Genomic Instability Paves the Way for Human Esophageal Carcinogenesis, Oncotarget, Vol. 7, No. 17, 24564–24571. doi:10.18632/oncotarget.8356.
  36. Rajarubendra, N., Lawrentschuk, N., Bolton, D. M., Klotz, L., and Davis, I. D. (2011). Prostate Cancer Immunology – an Update for Urologists, BJU International, Vol. 107, No. 7, 1046–1051. doi:10.1111/j.1464-410X.2010.09820.x.
  37. Elkord, E. (2007). Immunology and Immunotherapy Approaches for Prostate Cancer, Prostate Cancer and Prostatic Diseases, Vol. 10, No. 3, 224–236. doi:10.1038/sj.pcan.4500964.
  38. Liu, J., Fu, M., Wang, M., Wan, D., Wei, Y., and Wei, X. (2022). Cancer Vaccines as Promising Immuno-Therapeutics: Platforms and Current Progress, Journal of Hematology & Oncology, Vol. 15, No. 1, 28. doi:10.1186/s13045-022-01247-x.
  39. Li, M. (2024). The Mechanism of Action of Cancer Therapeutic Vaccines and Their Application Prospects, Transactions on Materials, Biotechnology and Life Sciences, Vol. 3, 694–700. doi:10.62051/2w95tb51.
  40. Melssen, M., and Slingluff, C. L. (2017). Vaccines Targeting Helper T Cells for Cancer Immunotherapy, Current Opinion in Immunology, Vol. 47, 85–92. doi:10.1016/j.coi.2017.07.004.
  41. Ostrand-Rosenberg, S. (2005). CD4+ T Lymphocytes: A Critical Component of Antitumor Immunity, Cancer Investigation, Vol. 23, No. 5, 413–419. doi:10.1081/CNV-67428.
  42. Raskov, H., Orhan, A., Christensen, J. P., and Gögenur, I. (2021). Cytotoxic CD8+ T Cells in Cancer and Cancer Immunotherapy, British Journal of Cancer, Vol. 124, No. 2, 359–367. doi:10.1038/s41416-020-01048-4.
  43. Vacca, P., Munari, E., Tumino, N., Moretta, F., Pietra, G., Vitale, M., Del Zotto, G., Mariotti, F. R., Mingari, M. C., and Moretta, L. (2018). Human Natural Killer Cells and Other Innate Lymphoid Cells in Cancer: Friends or Foes?, Immunology Letters, Vol. 201, 14–19. doi:10.1016/j.imlet.2018.11.004.
  44. Zöphel, D., Angenendt, A., Kaschek, L., Ravichandran, K., Hof, C., Janku, S., Hoth, M., and Lis, A. (2022). Faster Cytotoxicity with Age: Increased Perforin and Granzyme Levels in Cytotoxic CD8 + T Cells Boost Cancer Cell Elimination, Aging Cell, Vol. 21, No. 8, e13668. doi:10.1111/acel.13668.
  45. Palmer, D. C., Balasubramaniam, S., Hanada, K., Wrzesinski, C., Yu, Z., Farid, S., Theoret, M. R., Hwang, L. N., Klebanoff, C. A., Gattinoni, L., Goldstein, A. L., Yang, J. C., and Restifo, N. P. (2004). Vaccine-Stimulated, Adoptively Transferred CD8+ T Cells Traffic Indiscriminately and Ubiquitously While Mediating Specific Tumor Destruction1, The Journal of Immunology, Vol. 173, No. 12, 7209–7216. doi:10.4049/jimmunol.173.12.7209.
  46. Overwijk, W. W., Theoret, M. R., Finkelstein, S. E., Surman, D. R., de Jong, L. A., Vyth-Dreese, F. A., Dellemijn, T. A., Antony, P. A., Spiess, P. J., Palmer, D. C., Heimann, D. M., Klebanoff, C. A., Yu, Z., Hwang, L. N., Feigenbaum, L., Kruisbeek, A. M., Rosenberg, S. A., and Restifo, N. P. (2003). Tumor Regression and Autoimmunity after Reversal of a Functionally Tolerant State of Self-Reactive CD8+ T Cells, Journal of Experimental Medicine, Vol. 198, No. 4, 569–580. doi:10.1084/jem.20030590.
  47. Oh, D. Y., and Fong, L. (2021). Cytotoxic CD4+ T Cells in Cancer: Expanding the Immune Effector Toolbox, Immunity, Vol. 54, No. 12, 2701–2711. doi:10.1016/j.immuni.2021.11.015.
  48. Melssen, M., and Slingluff, C. L. (2017). Vaccines Targeting Helper T Cells for Cancer Immunotherapy, Current Opinion in Immunology, Vol. 47, 85–92. doi:10.1016/j.coi.2017.07.004.
  49. Tay, R. E., Richardson, E. K., and Toh, H. C. (2021). Revisiting the Role of CD4+ T Cells in Cancer Immunotherapy—New Insights into Old Paradigms, Cancer Gene Therapy, Vol. 28, No. 1, 5–17. doi:10.1038/s41417-020-0183-x.
  50. Kravtsov, D. S., Erbe, A. K., Sondel, P. M., and Rakhmilevich, A. L. (2022). Roles of CD4+ T Cells as Mediators of Antitumor Immunity, Frontiers in Immunology, Vol. 13. doi:10.3389/fimmu.2022.972021.
  51. Schirrmacher, V. (2020). New Insights into Mechanisms of Long-Term Protective Anti-Tumor Immunity Induced by Cancer Vaccines Modified by Virus Infection, Biomedicines, Vol. 8, No. 3, 55. doi:10.3390/biomedicines8030055.
  52. Heath, E. I., Thakur, A., Chen, W., Hwang, C., Paller, C. J., Cackowski, F. C., Boerner, J. L., Heilbrun, L., Smith, M. P., Schalk, D. L., Schienschang, A., Whitaker, S. A., Polend, A., Smith, D., Vaishampayan, U. N., Dickow, B., and Lum, L. G. (2024). Race-Related Differences in Sipuleucel-T Response among Men with Metastatic Castrate–Resistant Prostate Cancer, Cancer Research Communications, Vol. 4, No. 7, 1715–1725. doi:10.1158/2767-9764.CRC-24-0112.
  53. Kissick, H. T., Sanda, M. G., Dunn, L. K., and Arredouani, M. S. (2014). Immunization with a Peptide Containing MHC Class I and II Epitopes Derived from the Tumor Antigen SIM2 Induces an Effective CD4 and CD8 T-Cell Response, PLoS ONE, Vol. 9, No. 4, e93231. doi:10.1371/journal.pone.0093231.
  54. Zhang, B., Liu, J., Mo, Y., Zhang, K., Huang, B., and Shang, D. (2024). CD8+ T Cell Exhaustion and Its Regulatory Mechanisms in the Tumor Microenvironment: Key to the Success of Immunotherapy, Frontiers in Immunology, Vol. 15, 1476904. doi:10.3389/fimmu.2024.1476904.
  55. Jiang, Y., Li, Y., and Zhu, B. (2015). T-Cell Exhaustion in the Tumor Microenvironment, Cell Death & Disease, Vol. 6, No. 6, e1792–e1792. doi:10.1038/cddis.2015.162.
  56. Stone, L. (2023). Singling out the Immune-Suppressive TME in Prostate Cancer, Nature Reviews Urology, Vol. 20, No. 4, 199–199. doi:10.1038/s41585-023-00758-7.
  57. Wang, C., Singer, M., and Anderson, A. C. (2017). Molecular Dissection of CD8+ T Cell Dysfunction, Trends in Immunology, Vol. 38, No. 8, 567–576. doi:10.1016/j.it.2017.05.008.
  58. Zhang, Z., Liu, S., Zhang, B., Qiao, L., Zhang, Y., and Zhang, Y. (2020). T Cell Dysfunction and Exhaustion in Cancer, Frontiers in Cell and Developmental Biology, Vol. 8, 17. doi:10.3389/fcell.2020.00017.
  59. Minev, B., and Salgaller, M. L. (2004). Vaccines for the Immunotherapy of Prostate Cancer, M. A. Morse; T. M. Clay; H. K. Lyerly (Eds.), Handbook of Cancer Vaccines, Humana Press, Totowa, NJ, 451–464. doi:10.1007/978-1-59259-680-5_29.
  60. Daniels, T., Zhang, J., Gutierrez, I., Elliot, M. L., Yamada, B., Heeb, M. J., Sheets, S. M., Wu, X., and Casiano, C. A. (2005). Antinuclear Autoantibodies in Prostate Cancer: Immunity to LEDGF/P75, a Survival Protein Highly Expressed in Prostate Tumors and Cleaved during Apoptosis, The Prostate, Vol. 62, No. 1, 14–26. doi:10.1002/pros.20112.
  61. Cozzi, P., Kearsley, J., and Li, Y. (2008). Overview of Tumor-Associated Antigens (TAAs) as Potential Therapeutic Targets for Prostate Cancer Therapy, Current Cancer Therapy Reviews, Vol. 4, No. 4, 271–284. doi:10.2174/157339408786413371.
  62. Lopez Bujanda, Z. (Areli), Obradovic, A., Nirschl, T., O’Donnell, T., Laserson, U., Macedo-Gonzales, R., Reshef, R., Yuan, T., Soni, M., Antonarakis, E., Larman, B., Muranski, P., Drake, C., and Lopez Bujanda, Z. (Areli). (2020). 168 A Novel Prostate-Restricted Tumor-Associated Antigen: A Potential Therapeutic Target, Regular and Young Investigator Award AbstractsPresented at the 35th Anniversary Annual Meeting (SITC 2020), , BMJ Publishing Group Ltd, A101–A101. doi:10.1136/jitc-2020-SITC2020.0168.
  63. Ghosh, A., Wang, X., Klein, E., and Heston, W. D. W. (2005). Novel Role of Prostate-Specific Membrane Antigen in Suppressing Prostate Cancer Invasiveness, Cancer Research, Vol. 65, No. 3, 727–731. doi:10.1158/0008-5472.727.65.3.
  64. Mhawech-Fauceglia, P., Zhang, S., Terracciano, L., Sauter, G., Chadhuri, A., Herrmann, F. R., and Penetrante, R. (2007). Prostate-Specific Membrane Antigen (PSMA) Protein Expression in Normal and Neoplastic Tissues and Its Sensitivity and Specificity in Prostate Adenocarcinoma: An Immunohistochemical Study Using Mutiple Tumour Tissue Microarray Technique, Histopathology, Vol. 50, No. 4, 472–483. doi:10.1111/j.1365-2559.2007.02635.x.
  65. Giraudet, A.-L., Kryza, D., Hofman, M., Moreau, A., Fizazi, K., Flechon, A., Hicks, R. J., and Tran, B. (2021). PSMA Targeting in Metastatic Castration-Resistant Prostate Cancer: Where Are We and Where Are We Going?, Therapeutic Advances in Medical Oncology, Vol. 13, 17588359211053898. doi:10.1177/17588359211053898.
  66. Tagawa, S. T., Beltran, H., Vallabhajosula, S., Goldsmith, S. J., Osborne, J., Matulich, D., Petrillo, K., Parmar, S., Nanus, D. M., and Bander, N. H. (2010). Anti-Prostate Specific Membrane Antigen-Based Radioimmunotherapy for Prostate Cancer, Cancer, Vol. 116, No. 4 Suppl, 1075–1083. doi:10.1002/cncr.24795.
  67. Vu, P. L., Vadakekolathu, J., Idri, S., Nicholls, H., Cavaignac, M., Reeder, S., Khan, M. A., Christensen, D., Pockley, A. G., and McArdle, S. E. (2022). A Mutated Prostatic Acid Phosphatase (PAP) Peptide-Based Vaccine Induces PAP-Specific CD8+ T Cells with Ex Vivo Cytotoxic Capacities in HHDII/DR1 Transgenic Mice, Cancers, Vol. 14, No. 8, 1970. doi:10.3390/cancers14081970.
  68. Ercole, C. J., Lange, P. H., Mathisen, M., Chiou, R. K., Reddy, P. K., and Vessella, R. L. (1987). Prostatic Specific Antigen and Prostatic Acid Phosphatase in the Monitoring and Staging of Patients with Prostatic Cancer, The Journal of Urology, Vol. 138, No. 5, 1181–1184. doi:10.1016/s0022-5347(17)43543-9.
  69. Höti, N., Lih, T.-S., Dong, M., Zhang, Z., Mangold, L., Partin, A. W., Sokoll, L. J., Kay Li, Q., and Zhang, H. (2023). Urinary PSA and Serum PSA for Aggressive Prostate Cancer Detection, Cancers, Vol. 15, No. 3, 960. doi:10.3390/cancers15030960.
  70. Merriel, S. W. D., Pocock, L., Gilbert, E., Creavin, S., Walter, F. M., Spencer, A., and Hamilton, W. (2022). Systematic Review and Meta-Analysis of the Diagnostic Accuracy of Prostate-Specific Antigen (PSA) for the Detection of Prostate Cancer in Symptomatic Patients, BMC Medicine, Vol. 20, 54. doi:10.1186/s12916-021-02230-y.
  71. Merkens, L., Sailer, V., Lessel, D., Janzen, E., Greimeier, S., Kirfel, J., Perner, S., Pantel, K., Werner, S., and von Amsberg, G. (2022). Aggressive Variants of Prostate Cancer: Underlying Mechanisms of Neuroendocrine Transdifferentiation, Journal of Experimental & Clinical Cancer Research, Vol. 41, No. 1, 46. doi:10.1186/s13046-022-02255-y.
  72. Yamasaki, S., Shimizu, K., and Fujii, S.-I. (2024). Tumor Epitope Spreading by a Novel Multivalent Therapeutic Cellular Vaccine Targeting Cancer Antigens to Invariant NKT-Triggered Dendritic Cells in Situ, Frontiers in Immunology, Vol. 15, 1345037. doi:10.3389/fimmu.2024.1345037.
  73. St. John, J., Powell, K., Conley-LaComb, M. K., and Chinni, S. R. (2012). TMPRSS2-ERG Fusion Gene Expression in Prostate Tumor Cells and Its Clinical and Biological Significance in Prostate Cancer Progression, Journal of Cancer Science & Therapy, Vol. 4, No. 4, 94–101. doi:10.4172/1948-5956.1000119.
  74. Bilusic, M., McMahon, S., Madan, R. A., Karzai, F., Tsai, Y.-T., Donahue, R. N., Palena, C., Jochems, C., Marté, J. L., Floudas, C., Strauss, J., Redman, J., Sater, H. A., Rabizadeh, S., Soon-Shiong, P., Schlom, J., and Gulley, J. L. (2021). Phase I Study of a Multitargeted Recombinant Ad5 PSA/MUC-1/Brachyury-Based Immunotherapy Vaccine in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC), Journal for ImmunoTherapy of Cancer, Vol. 9, No. 3, e002374. doi:10.1136/jitc-2021-002374.
  75. Gao, T., Cen, Q., and Lei, H. (2020). A Review on Development of MUC1-Based Cancer Vaccine, Biomedicine & Pharmacotherapy, Vol. 132, 110888. doi:10.1016/j.biopha.2020.110888.
  76. North, S. A., Graham, K., Bodnar, D., and Venner, P. (2006). A Pilot Study of the Liposomal MUC1 Vaccine BLP25 in Prostate Specific Antigen Failures After Radical Prostatectomy, The Journal of Urology, Vol. 176, No. 1, 91–95. doi:10.1016/S0022-5347(06)00494-0.
  77. Cai, Y., Chen, R., Gao, S., Li, W., Liu, Y., Su, G., Song, M., Jiang, M., Jiang, C., and Zhang, X. (2023). Artificial Intelligence Applied in Neoantigen Identification Facilitates Personalized Cancer Immunotherapy, Frontiers in Oncology, Vol. 12, 1054231. doi:10.3389/fonc.2022.1054231.
  78. Olawade, D. B., Teke, J., Fapohunda, O., Weerasinghe, K., Usman, S. O., Ige, A. O., and Clement David-Olawade, A. (2024). Leveraging Artificial Intelligence in Vaccine Development: A Narrative Review, Journal of Microbiological Methods, Vol. 224, 106998. doi:10.1016/j.mimet.2024.106998.
  79. Hu, Z., Leet, D. E., Allesøe, R. L., Oliveira, G., Li, S., Luoma, A. M., Liu, J., Forman, J., Huang, T., Iorgulescu, J. B., Holden, R., Sarkizova, S., Gohil, S. H., Redd, R. A., Sun, J., Elagina, L., Giobbie-Hurder, A., Zhang, W., Peter, L., Ciantra, Z., Rodig, S., Olive, O., Shetty, K., Pyrdol, J., Uduman, M., Lee, P. C., Bachireddy, P., Buchbinder, E. I., Yoon, C. H., Neuberg, D., Pentelute, B. L., Hacohen, N., Livak, K. J., Shukla, S. A., Olsen, L. R., Barouch, D. H., Wucherpfennig, K. W., Fritsch, E. F., Keskin, D. B., Wu, C. J., and Ott, P. A. (2021). Personal Neoantigen Vaccines Induce Persistent Memory T Cell Responses and Epitope Spreading in Patients with Melanoma, Nature Medicine, Vol. 27, No. 3, 515–525. doi:10.1038/s41591-020-01206-4.
  80. Kellermann, G., Leulliot, N., Cherfils-Vicini, J., Blaud, M., and Brest, P. (2024). Activated B-Cells Enhance Epitope Spreading to Support Successful Cancer Immunotherapy, Frontiers in Immunology, Vol. 15, 1382236. doi:10.3389/fimmu.2024.1382236.
  81. Jähnisch, H., Füssel, S., Kiessling, A., Wehner, R., Zastrow, S., Bachmann, M., Rieber, E. P., Wirth, M. P., and Schmitz, M. (2010). Dendritic Cell‐Based Immunotherapy for Prostate Cancer, Journal of Immunology Research, Vol. 2010, No. 1, 517493. doi:10.1155/2010/517493.
  82. Sutherland, S. I. M., Ju, X., Horvath, L. G., and Clark, G. J. (2021). Moving on From Sipuleucel-T: New Dendritic Cell Vaccine Strategies for Prostate Cancer, Frontiers in Immunology, Vol. 12, 641307. doi:10.3389/fimmu.2021.641307.
  83. Bakhshi, P., Nourizadeh, M., Sharifi, L., Nowroozi, M. R., Mohsenzadegan, M., and Farajollahi, M. M. (2024). Impaired Monocyte‐derived Dendritic Cell Phenotype in Prostate Cancer Patients: A Phenotypic Comparison with Healthy Donors, Cancer Reports, Vol. 7, No. 2, e1996. doi:10.1002/cnr2.1996.
  84. Caram, M. E. V., Ross, R., Lin, P., and Mukherjee, B. (2019). Factors Associated With Use of Sipuleucel-T to Treat Patients With Advanced Prostate Cancer, JAMA Network Open, Vol. 2, No. 4, e192589. doi:10.1001/jamanetworkopen.2019.2589.
  85. Anjum, S., Naseer, F., Ahmad, T., Liaquat, A., Abduh, M. S., and Kousar, K. (2024). Co‐delivery of Oncolytic Virus and Chemotherapeutic Modality: Vincristine against Prostate Cancer Treatment: A Potent Viro‐chemotherapeutic Approach, Journal of Medical Virology, Vol. 96, No. 7, e29748. doi:10.1002/jmv.29748.
  86. Graham, J. B. (2010, May). Co-delivery of cationic polymers and adenovirus in immunotherapy of prostate cancer (Doctor of Philosophy)University of Iowa, Iowa City, IA, United StatesRetrieved from https://iro.uiowa.edu/esploro/outputs/doctoral/9983777066502771.
  87. Sardinha, M., Palma Dos Reis, A. F., Barreira, J. V., Fontes Sousa, M., Pacey, S., and Luz, R. (2023). Antibody-Drug Conjugates in Prostate Cancer: A Systematic Review, Cureus. doi:10.7759/cureus.34490.
  88. D’Apice, L., Costa, V., Sartorius, R., Trovato, M., Aprile, M., and De Berardinis, P. (2015). Stimulation of Innate and Adaptive Immunity by Using Filamentous Bacteriophage Fd Targeted to DEC-205, Journal of Immunology Research, Vol. 2015, 1–11. doi:10.1155/2015/585078.
  89. Kim, J. J., Yang, J. S., Dang, K., Manson, K. H., and Weiner, D. B. (2001). Engineering Enhancement of Immune Responses to DNA-Based Vaccines in a Prostate Cancer Model in Rhesus Macaques through the Use of Cytokine Gene Adjuvants, Clinical Cancer Research: An Official Journal of the American Association for Cancer Research, Vol. 7, No. 3 Suppl, 882s–889s.
  90. Kübler, H., Scheel, B., Gnad-Vogt, U., Miller, K., Schultze-Seemann, W., Vom Dorp, F., Parmiani, G., Hampel, C., Wedel, S., Trojan, L., Jocham, D., Maurer, T., Rippin, G., Fotin-Mleczek, M., Von Der Mülbe, F., Probst, J., Hoerr, I., Kallen, K.-J., Lander, T., and Stenzl, A. (2015). Self-Adjuvanted mRNA Vaccination in Advanced Prostate Cancer Patients: A First-in-Man Phase I/IIa Study, Journal for Immunotherapy of Cancer, Vol. 3, No. 1, 26. doi:10.1186/s40425-015-0068-y.
  91. Hou, X., Zaks, T., Langer, R., and Dong, Y. (2021). Lipid Nanoparticles for mRNA Delivery, Nature Reviews Materials, Vol. 6, No. 12, 1078–1094. doi:10.1038/s41578-021-00358-0.
  92. Lu, B., Lim, J. M., Yu, B., Song, S., Neeli, P., Sobhani, N., K, P., Bonam, S. R., Kurapati, R., Zheng, J., and Chai, D. (2024). The Next-Generation DNA Vaccine Platforms and Delivery Systems: Advances, Challenges and Prospects, Frontiers in Immunology, Vol. 15, 1332939. doi:10.3389/fimmu.2024.1332939.
  93. Rakoczy, K., Kisielewska, M., Sędzik, M., Jonderko, L., Celińska, J., Sauer, N., Szlasa, W., Saczko, J., Novickij, V., and Kulbacka, J. (2022). Electroporation in Clinical Applications—The Potential of Gene Electrotransfer and Electrochemotherapy, Applied Sciences, Vol. 12, No. 21, 10821. doi:10.3390/app122110821.
  94. Larsen, S. E., Erasmus, J. H., Reese, V. A., Pecor, T., Archer, J., Kandahar, A., Hsu, F.-C., Nicholes, K., Reed, S. G., Baldwin, S. L., and Coler, R. N. (2023). An RNA-Based Vaccine Platform for Use against Mycobacterium Tuberculosis, Vaccines, Vol. 11, No. 1, 130. doi:10.3390/vaccines11010130.
  95. Leitner, W. W., Ying, H., and Restifo, N. P. (1999). DNA and RNA-Based Vaccines: Principles, Progress and Prospects, Vaccine, Vol. 18, Nos. 9–10, 765–777.
  96. Ahmad, S., Sweeney, P., Sullivan, G. C., and Tangney, M. (2012). DNA Vaccination for Prostate Cancer, from Preclinical to Clinical Trials - Where We Stand?, Genetic Vaccines and Therapy, Vol. 10, No. 1, 9. doi:10.1186/1479-0556-10-9.
  97. Colluru, V. T., Johnson, L. E., Olson, B. M., and McNeel, D. G. (2016). Preclinical and Clinical Development of DNA Vaccines for Prostate Cancer, Urologic Oncology: Seminars and Original Investigations, Vol. 34, No. 4, 193–204. doi:10.1016/j.urolonc.2013.09.014.
  98. Rausch, S., Schwentner, C., Stenzl, A., and Bedke, J. (2014). mRNA Vaccine CV9103 and CV9104 for the Treatment of Prostate Cancer, Human Vaccines & Immunotherapeutics, Vol. 10, No. 11, 3146–3152. doi:10.4161/hv.29553.
  99. Arlen, P. M., Gulley, J. L., Tsang, K.-Y., and Schlom, J. (2003). Strategies for the Development of PSA-Based Vaccines for the Treatment of Advanced Prostate Cancer, Expert Review of Vaccines, Vol. 2, No. 4, 483–493. doi:10.1586/14760584.2.4.483.
  100. Li, J., Sun, Y., Jia, T., Zhang, R., Zhang, K., and Wang, L. (2014). Messenger RNA Vaccine Based on Recombinant MS2 Virus‐like Particles against Prostate Cancer, International Journal of Cancer, Vol. 134, No. 7, 1683–1694. doi:10.1002/ijc.28482.
  101. Gao, Y., Yang, L., Li, Z., Peng, X., and Li, H. (2024). mRNA Vaccines in Tumor Targeted Therapy: Mechanism, Clinical Application, and Development Trends, Biomarker Research, Vol. 12, No. 1, 93. doi:10.1186/s40364-024-00644-3.
  102. Madan, R. A., Gulley, J. L., and Arlen, P. M. (2006). PSA-Based Vaccines for the Treatment of Prostate Cancer, Expert Review of Vaccines, Vol. 5, No. 2, 199–209. doi:10.1586/14760584.5.2.199.
  103. Skwarczynski, M., and Toth, I. (2016). Peptide-Based Synthetic Vaccines, Chemical Science, Vol. 7, No. 2, 842–854. doi:10.1039/c5sc03892h.
  104. Paston, S. J., Brentville, V. A., Symonds, P., and Durrant, L. G. (2021). Cancer Vaccines, Adjuvants, and Delivery Systems, Frontiers in Immunology, Vol. 12. doi:10.3389/fimmu.2021.627932.
  105. Abd-Aziz, N., and Poh, C. L. (2022). Development of Peptide-Based Vaccines for Cancer, Journal of Oncology, Vol. 2022, 9749363. doi:10.1155/2022/9749363.
  106. Potluri, H. K., Ng, T. L., Newton, M. A., and McNeel, D. G. (2022). GM-CSF Elicits Antibodies to Tumor-Associated Proteins When Used as a Prostate Cancer Vaccine Adjuvant, Cancer Immunology, Immunotherapy: CII, Vol. 71, No. 9, 2267–2275. doi:10.1007/s00262-022-03150-3.
  107. Disis, M. L., Bernhard, H., Shiota, F. M., Hand, S. L., Gralow, J. R., Huseby, E. S., Gillis, S., and Cheever, M. A. (1996). Granulocyte-Macrophage Colony-Stimulating Factor: An Effective Adjuvant for Protein and Peptide-Based Vaccines, Blood, Vol. 88, No. 1, 202–210.
  108. Obara, W., Sato, F., Takeda, K., Kato, R., Kato, Y., Kanehira, M., Takata, R., Mimata, H., Sugai, T., Nakamura, Y., and Fujioka, T. (2017). Phase I Clinical Trial of Cell Division Associated 1 ( CDCA 1) Peptide Vaccination for Castration Resistant Prostate Cancer, Cancer Science, Vol. 108, No. 7, 1452–1457. doi:10.1111/cas.13278.
  109. Hueman, M. T., Dehqanzada, Z. A., Novak, T. E., Gurney, J. M., Woll, M. M., Ryan, G. B., Storrer, C. E., Fisher, C., McLeod, D. G., Ioannides, C. G., Ponniah, S., and Peoples, G. E. (2005). Phase I Clinical Trial of a HER-2/ Neu Peptide (E75) Vaccine for the Prevention of Prostate-Specific Antigen Recurrence in High-Risk Prostate Cancer Patients, Clinical Cancer Research, Vol. 11, No. 20, 7470–7479. doi:10.1158/1078-0432.CCR-05-0235.
  110. Meye, A., Fuessel, S., Schmitz, M., Zastrow, S., Linne, C., Richter, K., Lobel, B., Hakenberg, O. W., Hoelig, K., Rieber, P. E., and Wirth, M. P. (2006). Vaccination of Hormone-Refractory Prostate Cancer Patients with Peptide Cocktail-Loaded Dendritic Cells: Results of a Phase I Clinical Trial, Journal of Clinical Oncology, Vol. 24, No. 18_suppl, 2551–2551. doi:10.1200/jco.2006.24.18_suppl.2551.
  111. Taylor, B. C., and Balko, J. M. (2022). Mechanisms of MHC-I Downregulation and Role in Immunotherapy Response, Frontiers in Immunology, Vol. 13. doi:10.3389/fimmu.2022.844866.
  112. Carretero, F. J., del Campo, A. B., Flores-Martín, J. F., Mendez, R., García-Lopez, C., Cozar, J. M., Adams, V., Ward, S., Cabrera, T., Ruiz-Cabello, F., Garrido, F., and Aptsiauri, N. (2015). Frequent HLA Class I Alterations in Human Prostate Cancer: Molecular Mechanisms and Clinical Relevance, Cancer Immunology, Immunotherapy : CII, Vol. 65, No. 1, 47–59. doi:10.1007/s00262-015-1774-5.
  113. Obara, W., Kanehira, M., Katagiri, T., Kato, R., Kato, Y., and Takata, R. (2018). Present Status and Future Perspective of Peptide‐based Vaccine Therapy for Urological Cancer, Cancer Science, Vol. 109, No. 3, 550–559. doi:10.1111/cas.13506.
  114. Mohite, P., Yadav, V., Pandhare, R., Maitra, S., Saleh, F. M., Saleem, R. M., Al-malky, H. S., Kumarasamy, V., Subramaniyan, V., Abdel-Daim, M. M., and Uti, D. E. (2024). Revolutionizing Cancer Treatment: Unleashing the Power of Viral Vaccines, Monoclonal Antibodies, and Proteolysis-Targeting Chimeras in the New Era of Immunotherapy, ACS Omega, Vol. 9, No. 7, 7277–7295. doi:10.1021/acsomega.3c06501.
  115. Ragothaman, M., and Yoo, S. Y. (2023). Engineered Phage-Based Cancer Vaccines: Current Advances and Future Directions, Vaccines, Vol. 11, No. 5, 919. doi:10.3390/vaccines11050919.
  116. Madan, R. A., Arlen, P. M., Mohebtash, M., Hodge, J. W., and Gulley, J. L. (2009). Prostvac-VF: A Vector-Based Vaccine Targeting PSA in Prostate Cancer, Expert Opinion on Investigational Drugs, Vol. 18, No. 7, 1001–1011. doi:10.1517/13543780902997928.
  117. Madan, R. A., Heery, C. R., and Gulley, J. L. (2014). Poxviral-Based Vaccine Elicits Immunologic Responses in Prostate Cancer Patients, OncoImmunology, Vol. 3, No. 5, e28611. doi:10.4161/onci.28611.
  118. Klyushnenkova, E. N., Kouiavskaia, D. V., Parkins, C. J., Caposio, P., Botto, S., Alexander, R. B., and Jarvis, M. A. (2012). A Cytomegalovirus-Based Vaccine Expressing a Single Tumor-Specific CD8+ T-Cell Epitope Delays Tumor Growth in a Murine Model of Prostate Cancer, Journal of Immunotherapy, Vol. 35, No. 5, 390–399. doi:10.1097/CJI.0b013e3182585d50.
  119. Sasso, E., D’Alise, A. M., Zambrano, N., Scarselli, E., Folgori, A., and Nicosia, A. (2020). New Viral Vectors for Infectious Diseases and Cancer, Seminars in Immunology, Vol. 50, 101430. doi:10.1016/j.smim.2020.101430.
  120. Lubaroff, D. M., Konety, B. R., Link, B., Gerstbrein, J., Madsen, T., Shannon, M., Howard, J., Paisley, J., Boeglin, D., Ratliff, T. L., and Williams, R. D. (2009). Phase I Clinical Trial of an Adenovirus/Prostate-Specific Antigen Vaccine for Prostate Cancer: Safety and Immunologic Results, Clinical Cancer Research, Vol. 15, No. 23, 7375–7380. doi:10.1158/1078-0432.CCR-09-1910.
  121. Kaufman, H. L., Wang, W., Manola, J., DiPaola, R. S., Ko, Y.-J., Sweeney, C., Whiteside, T. L., Schlom, J., Wilding, G., and Weiner, L. M. (2004). Phase II Randomized Study of Vaccine Treatment of Advanced Prostate Cancer (E7897): A Trial of the Eastern Cooperative Oncology Group, Journal of Clinical Oncology, Vol. 22, No. 11, 2122–2132. doi:10.1200/JCO.2004.08.083.
  122. Fukuhara, H., Homma, Y., and Todo, T. (2010). Oncolytic Virus Therapy for Prostate Cancer, International Journal of Urology, Vol. 17, No. 1, 20–30. doi:10.1111/j.1442-2042.2009.02383.x.
  123. Larocca, C., and Schlom, J. (2011). Viral Vector –Based Therapeutic Cancer Vaccines, Cancer Journal (Sudbury, Mass.), Vol. 17, No. 5, 359–371. doi:10.1097/PPO.0b013e3182325e63.
  124. Saxena, M., Van, T. T. H., Baird, F. J., Coloe, P. J., and Smooker, P. M. (2013). Pre-Existing Immunity against Vaccine Vectors – Friend or Foe?, Microbiology, Vol. 159, No. Pt 1, 1–11. doi:10.1099/mic.0.049601-0.
  125. Cappuccini, F., Bryant, R., Pollock, E., Carter, L., Verrill, C., Hollidge, J., Poulton, I., Baker, M., Mitton, C., Baines, A., Meier, A., Schmidt, G., Harrop, R., Protheroe, A., MacPherson, R., Kennish, S., Morgan, S., Vigano, S., Romero, P. J., Evans, T., Catto, J., Hamdy, F., Hill, A. V. S., and Redchenko, I. (2020). Safety and Immunogenicity of Novel 5T4 Viral Vectored Vaccination Regimens in Early Stage Prostate Cancer: A Phase I Clinical Trial, Journal for ImmunoTherapy of Cancer, Vol. 8, No. 1, e000928. doi:10.1136/jitc-2020-000928.
  126. Schuhmacher, J., Heidu, S., Balchen, T., Richardson, J. R., Schmeltz, C., Sonne, J., Schweiker, J., Rammensee, H.-G., Thor Straten, P., Røder, M. A., Brasso, K., and Gouttefangeas, C. (2020). Vaccination against RhoC Induces Long-Lasting Immune Responses in Patients with Prostate Cancer: Results from a Phase I/II Clinical Trial, Journal for ImmunoTherapy of Cancer, Vol. 8, No. 2, e001157. doi:10.1136/jitc-2020-001157.
  127. Gulley, J. L., Borre, M., Vogelzang, N. J., Ng, S., Agarwal, N., Parker, C. C., Pook, D. W., Rathenborg, P., Flaig, T. W., Carles, J., Saad, F., Shore, N. D., Chen, L., Heery, C. R., Gerritsen, W. R., Priou, F., Langkilde, N. C., Novikov, A., and Kantoff, P. W. (2019). Phase III Trial of PROSTVAC in Asymptomatic or Minimally Symptomatic Metastatic Castration-Resistant Prostate Cancer, Journal of Clinical Oncology, Vol. 37, No. 13, 1051–1061. doi:10.1200/JCO.18.02031.
  128. Vilaça, M., Correia Pinto, J., Magalhães, H., Reis, F., and Mesquita, A. (n.d.). Tumor-Infiltrating Lymphocytes in Localized Prostate Cancer: Do They Play an Important Role?, Cureus, Vol. 15, No. 1, e34007. doi:10.7759/cureus.34007.
  129. Mao, C., Ding, Y., and Xu, N. (2021). A Double-Edged Sword Role of Cytokines in Prostate Cancer Immunotherapy, Frontiers in Oncology, Vol. 11, 688489. doi:10.3389/fonc.2021.688489.
  130. Jiang, W., He, Y., He, W., Wu, G., Zhou, X., Sheng, Q., Zhong, W., Lu, Y., Ding, Y., Lu, Q., Ye, F., and Hua, H. (2021). Exhausted CD8+T Cells in the Tumor Immune Microenvironment: New Pathways to Therapy, Frontiers in Immunology, Vol. 11, 622509. doi:10.3389/fimmu.2020.622509.
  131. Mantovani, A., Romero, P., Palucka, A. K., and Marincola, F. M. (2008). Tumour Immunity: Effector Response to Tumour and Role of the Microenvironment, Lancet (London, England), Vol. 371, No. 9614, 771–783. doi:10.1016/S0140-6736(08)60241-X.
  132. Thomas, R., Jerome, J. M., Krieger, K. L., Ashraf, N., and Rowley, D. R. (2024). The Reactive Stroma Response Regulates the Immune Landscape in Prostate Cancer, Journal of Translational Genetics and Genomics, Vol. 8, No. 3, 249–277. doi:10.20517/jtgg.2024.15.
  133. Tie, Y., Tang, F., Wei, Y., and Wei, X. (2022). Immunosuppressive Cells in Cancer: Mechanisms and Potential Therapeutic Targets, Journal of Hematology & Oncology, Vol. 15, No. 1, 61. doi:10.1186/s13045-022-01282-8.
  134. Kim, S. K., and Cho, S. W. (2022). The Evasion Mechanisms of Cancer Immunity and Drug Intervention in the Tumor Microenvironment, Frontiers in Pharmacology, Vol. 13, 868695. doi:10.3389/fphar.2022.868695.
  135. Zahm, C. D., Moseman, J. E., Delmastro, L. E., and G. Mcneel, D. (n.d.). PD-1 and LAG-3 Blockade Improve Anti-Tumor Vaccine Efficacy, Oncoimmunology, Vol. 10, No. 1, 1912892. doi:10.1080/2162402X.2021.1912892.
  136. Japp, A. S., Kursunel, M. A., Meier, S., Mälzer, J. N., Li, X., Rahman, N. A., Jekabsons, W., Krause, H., Magheli, A., Klopf, C., Thiel, A., and Frentsch, M. (2015). Dysfunction of PSA-Specific CD8+ T Cells in Prostate Cancer Patients Correlates with CD38 and Tim-3 Expression, Cancer Immunology, Immunotherapy : CII, Vol. 64, No. 11, 1487–1494. doi:10.1007/s00262-015-1752-y.
  137. Bettonville, M., d’Aria, S., Weatherly, K., Porporato, P. E., Zhang, J., Bousbata, S., Sonveaux, P., and Braun, M. Y. (n.d.). Long-Term Antigen Exposure Irreversibly Modifies Metabolic Requirements for T Cell Function, eLife, Vol. 7, e30938. doi:10.7554/eLife.30938.
  138. Mulvey, A., Muggeo-Bertin, E., Berthold, D. R., and Herrera, F. G. (2022). Overcoming Immune Resistance With Radiation Therapy in Prostate Cancer, Frontiers in Immunology, Vol. 13, 859785. doi:10.3389/fimmu.2022.859785.
  139. Gujar, S. A., Pan, D., Marcato, P., Garant, K. A., and Lee, P. W. (2011). Oncolytic Virus-Initiated Protective Immunity Against Prostate Cancer, Molecular Therapy, Vol. 19, No. 4, 797–804. doi:10.1038/mt.2010.297.
  140. Fu, R., Qi, R., Xiong, H., Lei, X., Jiang, Y., He, J., Chen, F., Zhang, L., Qiu, D., Chen, Y., Nie, M., Guo, X., Zhu, Y., Zhang, J., Yue, M., Cao, J., Wang, G., Que, Y., Fang, M., Wang, Y., Chen, Y., Cheng, T., Ge, S., Zhang, J., Yuan, Q., Zhang, T., and Xia, N. (2024). Combination Therapy with Oncolytic Virus and T Cells or mRNA Vaccine Amplifies Antitumor Effects, Signal Transduction and Targeted Therapy, Vol. 9, No. 1, 1–14. doi:10.1038/s41392-024-01824-1.
  141. Tan, S., Wang, K., Sun, F., Li, Y., and Gao, Y. (2018). CXCL9 Promotes Prostate Cancer Progression through Inhibition of Cytokines from T Cells, Molecular Medicine Reports, Vol. 18, No. 2, 1305–1310. doi:10.3892/mmr.2018.9152.
  142. Bronger, H., Singer, J., Windmüller, C., Reuning, U., Zech, D., Delbridge, C., Dorn, J., Kiechle, M., Schmalfeldt, B., Schmitt, M., and Avril, S. (2016). CXCL9 and CXCL10 Predict Survival and Are Regulated by Cyclooxygenase Inhibition in Advanced Serous Ovarian Cancer, British Journal of Cancer, Vol. 115, No. 5, 553–563. doi:10.1038/bjc.2016.172.
  143. Madan, R. A., Gulley, J. L., Schlom, J., Steinberg, S. M., Liewehr, D. J., Dahut, W. L., and Arlen, P. M. (2008). Analysis of Overall Survival in Patients with Nonmetastatic Castration-Resistant Prostate Cancer Treated with Vaccine, Nilutamide, and Combination Therapy, Clinical Cancer Research, Vol. 14, No. 14, 4526–4531. doi:10.1158/1078-0432.CCR-07-5048.
  144. Bhasin, A., Mille, P. J., Eturi, A., Iskander, A., Tester, W., and Zarrabi, K. K. (2024). Tumor-Associated Antigen Targets for Novel Immune-Based Strategies in Prostate Cancer, Journal of Translational Genetics and Genomics, Vol. 8, No. 1, 55–76. doi:10.20517/jtgg.2023.46.
  145. Kiessling, A., Wehner, R., Füssel, S., Bachmann, M., Wirth, M. P., and Schmitz, M. (2012). Tumor-Associated Antigens for Specific Immunotherapy of Prostate Cancer, Cancers, Vol. 4, No. 1, 193–217. doi:10.3390/cancers4010193.
  146. Liu, J., Li, Y., Yang, D., Yang, C., and Mao, L. (2019). Current State of Biomarkers for the Diagnosis and Assessment of Treatment Efficacy of Prostate Cancer, Discovery Medicine, Vol. 27, No. 150, 235–243.
  147. Sheikh, N. A., Petrylak, D., Kantoff, P. W., dela Rosa, C., Stewart, F. P., Kuan, L.-Y., Whitmore, J. B., Trager, J. B., Poehlein, C. H., Frohlich, M. W., and Urdal, D. L. (2012). Sipuleucel-T Immune Parameters Correlate with Survival: An Analysis of the Randomized Phase 3 Clinical Trials in Men with Castration-Resistant Prostate Cancer, Cancer Immunology, Immunotherapy : CII, Vol. 62, No. 1, 137–147. doi:10.1007/s00262-012-1317-2.
  148. Cha, E., and Fong, L. (2011). Immunotherapy for Prostate Cancer: Biology and Therapeutic Approaches, Journal of Clinical Oncology, Vol. 29, No. 27, 3677–3685. doi:10.1200/JCO.2010.34.5025.
  149. Le, D. T., and Jaffee, E. M. (2013). Next-Generation Cancer Vaccine Approaches: Integrating Lessons Learned From Current Successes With Promising Biotechnologic Advances, Journal of the National Comprehensive Cancer Network : JNCCN, Vol. 11, No. 7, 766–772.
  150. Wang, J., Zhou, K., Zhu, H., Wei, F., Ma, S., Kan, Y., Li, B., and Mao, L. (2023). Current Status and Progress of the Development of Prostate Cancer Vaccines, Journal of Cancer, Vol. 14, No. 5, 835–842. doi:10.7150/jca.80803.
  151. Reichmuth, A. M., Oberli, M. A., Jaklenec, A., Langer, R., and Blankschtein, D. (2016). mRNA Vaccine Delivery Using Lipid Nanoparticles, Therapeutic Delivery, Vol. 7, No. 5, 319–334. doi:10.4155/tde-2016-0006.
  152. Small, E. J., and Fong, L. (2010). Developing Immunotherapy As Legitimate Therapy for Patients With Prostate Cancer, Journal of Clinical Oncology, Vol. 28, No. 7, 1085–1087. doi:10.1200/JCO.2009.26.3483.
  153. Yun, J. W., Lee, S., Ryu, D., Park, S., Park, W.-Y., Joung, J.-G., and Jeong, J. (2018). Biomarkers Associated with Tumor Heterogeneity in Prostate Cancer, Translational Oncology, Vol. 12, No. 1, 43–48. doi:10.1016/j.tranon.2018.09.003.
  154. Kim, J. W., and Gulley, J. L. (2012). Poxviral Vectors for Cancer Immunotherapy, Expert Opinion on Biological Therapy, Vol. 12, No. 4, 463–478. doi:10.1517/14712598.2012.668516.
  155. Bou-Dargham, M. J., Sha, L., Sang, Q.-X. A., and Zhang, J. (2020). Immune Landscape of Human Prostate Cancer: Immune Evasion Mechanisms and Biomarkers for Personalized Immunotherapy, BMC Cancer, Vol. 20, No. 1, 572. doi:10.1186/s12885-020-07058-y.
  156. Reva, B. A., Omelchenko, T., Nair, S. S., and Tewari, A. K. (2020). Immune Escape in Prostate Cancer: Known and Predicted Mechanisms and Targets, Urologic Clinics of North America, Vol. 47, Nos. 4, Supplement, e9–e16. doi:10.1016/j.ucl.2020.10.004.
  157. Zhang, H., Patenaude, B., Ma, C., and Fang, H. (2023). Vaccine Pricing Strategies in China, BMJ Global Health, Vol. 8, No. 7, e011405. doi:10.1136/bmjgh-2022-011405.
  158. Jaroslawski, S., Caban, A., and Toumi, M. (2015). Sipuleucel-T (Provenge®): Autopsy of an Innovative Change of Paradigm in Cancer Treatment, Value in Health, Vol. 18, No. 7, A479. doi:10.1016/j.jval.2015.09.1294.
  159. Baghdadi, R. (2010). Dendreon vs CMS: Why the Provenge Coverage Controversy Is Bigger than Just One Product, Oncology (Williston Park, N.Y.), Vol. 24, No. 10, 881–883.
  160. Madan, R. A., and Gulley, J. L. (2011). Sipuleucel-T: Harbinger of a New Age of Therapeutics for Prostate Cancer, Expert Review of Vaccines, Vol. 10, No. 2, 141–150. doi:10.1586/erv.10.173.
  161. Andrews, A. (2015). Treating with Checkpoint Inhibitors—Figure $1 Million per Patient, American Health & Drug Benefits, Vol. 8, No. Spec Issue, 9.
  162. Paul, J., Mitchell, A. P., Kesselheim, A. S., and Rome, B. N. (2024). Trends in Prices of Checkpoint Inhibitors in the US, 2016-2023., Journal of Clinical Oncology, Vol. 42, No. 16_suppl, 11075–11075. doi:10.1200/JCO.2024.42.16_suppl.11075.
  163. PROSTVAC Misses Phase III Goal in Prostate Cancer. (2017, September 15). OncLive, from https://www.onclive.com/view/prostvac-misses-phase-iii-goal-in-prostate-cancer, accessed 9-2-2025.
  164. Vatsan, R. S., Bross, P. F., Liu, K., Theoret, M., De Claro, A. R., Lu, J., Helms, W., Niland, B., Husain, S. R., and Puri, R. K. (2013). Regulation of Immunotherapeutic Products for Cancer and FDA’s Role in Product Development and Clinical Evaluation, Journal for Immunotherapy of Cancer, Vol. 1, 5. doi:10.1186/2051-1426-1-5.
  165. Gignac, G. A., Morris, M. J., Heller, G., Schwartz, L. H., and Scher, H. I. (2008). Assessing Outcomes in Prostate Cancer Clinical Trials: A Twenty‐first Century Tower of Babel, Cancer, Vol. 113, No. 5, 966–974. doi:10.1002/cncr.23719.
  166. Halabi, S., Vogelzang, N. J., Ou, S.-S., Owzar, K., Archer, L., and Small, E. J. (2009). Progression-Free Survival as a Predictor of Overall Survival in Men With Castrate-Resistant Prostate Cancer, Journal of Clinical Oncology, Vol. 27, No. 17, 2766–2771. doi:10.1200/JCO.2008.18.9159.
  167. Yoshimura, K., Minami, T., Nozawa, M., Kimura, T., Egawa, S., Fujimoto, H., Yamada, A., Itoh, K., and Uemura, H. (2016). A Phase 2 Randomized Controlled Trial of Personalized Peptide Vaccine Immunotherapy with Low-Dose Dexamethasone Versus Dexamethasone Alone in Chemotherapy-Naive Castration-Resistant Prostate Cancer, European Urology, Vol. 70, No. 1, 35–41. doi:10.1016/j.eururo.2015.12.050.
  168. Rehman, L. ur, Nisar, M. H., Fatima, W., Sarfraz, A., Azeem, N., Sarfraz, Z., Robles-Velasco, K., and Cherrez-Ojeda, I. (2023). Immunotherapy for Prostate Cancer: A Current Systematic Review and Patient Centric Perspectives, Journal of Clinical Medicine, Vol. 12, No. 4, 1446. doi:10.3390/jcm12041446.
  169. Halabi, S., Roy, A., Rydzewska, L., Guo, S., Godolphin, P., Hussain, M., Tangen, C., Thompson, I., Xie, W., Carducci, M. A., Smith, M. R., Morris, M. J., Gravis, G., Dearnaley, D. P., Verhagen, P., Goto, T., James, N., Buyse, M. E., Tierney, J. F., Sweeney, C., and Collaboration, on behalf of the S. (2024). Radiographic Progression-Free Survival and Clinical Progression-Free Survival as Potential Surrogates for Overall Survival in Men With Metastatic Hormone-Sensitive Prostate Cancer, Journal of Clinical Oncology. doi:10.1200/JCO.23.01535.
  170. Redman, J. M., Gulley, J. L., and Madan, R. A. (2017). Combining Immunotherapies for the Treatment of Prostate Cancer, Urologic Oncology: Seminars and Original Investigations, Vol. 35, No. 12, 694–700. doi:10.1016/j.urolonc.2017.09.024.
  171. Antonarakis, E. S. (2012). Combining Active Immunotherapy with Immune Checkpoint Blockade for the Treatment of Advanced Prostate Cancer, Asian Journal of Andrology, Vol. 14, No. 4, 520–521. doi:10.1038/aja.2012.45.
  172. Singh, B. H., and Gulley, J. L. (2014). Therapeutic Vaccines as a Promising Treatment Modality against Prostate Cancer: Rationale and Recent Advances, Therapeutic Advances in Vaccines, Vol. 2, No. 5, 137–148. doi:10.1177/2051013614539478.
  173. Collins, J. M., Redman, J. M., and Gulley, J. L. (2018). Combining Vaccines and Immune Checkpoint Inhibitors to Prime, Expand, and Facilitate Effective Tumor Immunotherapy, Expert Review of Vaccines, Vol. 17, No. 8, 697–705. doi:10.1080/14760584.2018.1506332.
  174. Cecil, D. L., Curtis, B., Gad, E., Gormley, M., Timms, A. E., Corulli, L., Bos, R., Damle, R. N., Sepulveda, M. A., and Disis, M. L. (2022). Anti-Tumor Activity of a T-Helper 1 Multiantigen Vaccine in a Murine Model of Prostate Cancer, Scientific Reports, Vol. 12, No. 1, 13618. doi:10.1038/s41598-022-17950-1.
  175. Zhang, L. (2018). Multi-Epitope Vaccines: A Promising Strategy against Tumors and Viral Infections, Cellular and Molecular Immunology, Vol. 15, No. 2, 182–184. doi:10.1038/cmi.2017.92.
  176. Pfeifer, B. A., Beitelshees, M., Hill, A., Bassett, J., and Jones, C. H. (2023). Harnessing Synthetic Biology for Advancing RNA Therapeutics and Vaccine Design, Npj Systems Biology and Applications, Vol. 9, No. 1, 60. doi:10.1038/s41540-023-00323-3.
  177. Ravindranathan, D., Russler, G. A., Yantorni, L., Drusbosky, L. M., and Bilen, M. A. (2021). Detection of Microsatellite Instability via Circulating Tumor DNA and Response to Immunotherapy in Metastatic Castration-Resistant Prostate Cancer: A Case Series, Case Reports in Oncology, Vol. 14, No. 1, 190–196. doi:10.1159/000512819.
  178. Nisar, S., Bhat, A. A., Hashem, S., Yadav, S. K., Rizwan, A., Singh, M., Bagga, P., Macha, M. A., Frenneaux, M. P., Reddy, R., and Haris, M. (2020). Non-Invasive Biomarkers for Monitoring the Immunotherapeutic Response to Cancer, Journal of Translational Medicine, Vol. 18, No. 1, 471. doi:10.1186/s12967-020-02656-7.
  179. Abelin, J. G., Keskin, D. B., Sarkizova, S., Hartigan, C. R., Zhang, W., Sidney, J., Stevens, J., Lane, W., Zhang, G. L., Eisenhaure, T. M., Clauser, K. R., Hacohen, N., Rooney, M. S., Carr, S. A., and Wu, C. J. (2017). Mass Spectrometry Profiling of HLA-Associated Peptidomes in Mono-Allelic Cells Enables More Accurate Epitope Prediction, Immunity, Vol. 46, No. 2, 315–326. doi:10.1016/j.immuni.2017.02.007.
  180. Li, Y., Wu, X., Fang, D., and Luo, Y. (2024). Informing Immunotherapy with Multi-Omics Driven Machine Learning, Npj Digital Medicine, Vol. 7, No. 1, 1–16. doi:10.1038/s41746-024-01043-6.
  181. Kumar, A., Dixit, S., Srinivasan, K., M, D., and Vincent, P. M. D. R. (2024). Personalized Cancer Vaccine Design Using AI-Powered Technologies, Frontiers in Immunology, Vol. 15, 1357217. doi:10.3389/fimmu.2024.1357217.
  182. Jin, L., Zhou, Y., Zhang, S., and Chen, S.-J. (2025). mRNA Vaccine Sequence and Structure Design and Optimization: Advances and Challenges, Journal of Biological Chemistry, Vol. 301, No. 1, 108015. doi:10.1016/j.jbc.2024.108015.
  183. Chen, H., Ren, X., Xu, S., Zhang, D., and Han, T. (2022). Optimization of Lipid Nanoformulations for Effective mRNA Delivery, International Journal of Nanomedicine, Vol. 17, 2893–2905. doi:10.2147/IJN.S363990.
  184. Asrani, K. H., Farelli, J. D., Stahley, M. R., Miller, R. L., Cheng, C. J., Subramanian, R. R., and Brown, J. M. (2018). Optimization of mRNA Untranslated Regions for Improved Expression of Therapeutic mRNA, RNA Biology, Vol. 15, No. 6, 756–762. doi:10.1080/15476286.2018.1450054.
  185. Uchikov, P., Khalid, U., Dedaj-Salad, G. H., Ghale, D., Rajadurai, H., Kraeva, M., Kraev, K., Hristov, B., Doykov, M., Mitova, V., Bozhkova, M., Markov, S., and Stanchev, P. (2024). Artificial Intelligence in Breast Cancer Diagnosis and Treatment: Advances in Imaging, Pathology, and Personalized Care, Life, Vol. 14, No. 11, 1451. doi:10.3390/life14111451.
  186. Zhang, W.-Y., Zheng, X.-L., Coghi, P. S., Chen, J.-H., Dong, B.-J., and Fan, X.-X. (2024). Revolutionizing Adjuvant Development: Harnessing AI for next-Generation Cancer Vaccines, Frontiers in Immunology, Vol. 15. doi:10.3389/fimmu.2024.1438030.
  187. Zheng, Y., Ma, Y., Xiong, Q., Zhu, K., Weng, N., and Zhu, Q. (2024). The Role of Artificial Intelligence in the Development of Anticancer Therapeutics from Natural Polyphenols: Current Advances and Future Prospects, Pharmacological Research, Vol. 208, 107381. doi:10.1016/j.phrs.2024.107381.
  188. Bhinder, B., Gilvary, C., Madhukar, N. S., and Elemento, O. (2021). Artificial Intelligence in Cancer Research and Precision Medicine, Cancer Discovery, Vol. 11, No. 4, 900–915. doi:10.1158/2159-8290.CD-21-0090.
  189. Hanna, M. G., Pantanowitz, L., Jackson, B., Palmer, O., Visweswaran, S., Pantanowitz, J., Deebajah, M., and Rashidi, H. H. (2025). Ethical and Bias Considerations in Artificial Intelligence/Machine Learning, Modern Pathology, Vol. 38, No. 3, 100686. doi:10.1016/j.modpat.2024.100686.
  190. Stafie, C. S., Sufaru, I.-G., Ghiciuc, C. M., Stafie, I.-I., Sufaru, E.-C., Solomon, S. M., and Hancianu, M. (2023). Exploring the Intersection of Artificial Intelligence and Clinical Healthcare: A Multidisciplinary Review, Diagnostics, Vol. 13, No. 12, 1995. doi:10.3390/diagnostics13121995.
  191. Kumar, A., Dixit, S., Srinivasan, K., M, D., and Vincent, P. M. D. R. (2024). Personalized Cancer Vaccine Design Using AI-Powered Technologies, Frontiers in Immunology, Vol. 15. doi:10.3389/fimmu.2024.1357217.
  192. Doehn, C., Böhmer, T., Kausch, I., Sommerauer, M., and Jocham, D. (2008). Prostate Cancer Vaccines: Current Status and Future Potential, BioDrugs, Vol. 22, No. 2, 71–84. doi:10.2165/00063030-200822020-00001.
  193. Redman, J. M., Gulley, J. L., and Madan, R. A. (2017). Combining Immunotherapies for the Treatment of Prostate Cancer, Urologic Oncology, Vol. 35, No. 12, 694–700. doi:10.1016/j.urolonc.2017.09.024.
  194. Fan, T., Zhang, M., Yang, J., Zhu, Z., Cao, W., and Dong, C. (2023). Therapeutic Cancer Vaccines: Advancements, Challenges and Prospects, Signal Transduction and Targeted Therapy, Vol. 8, No. 1, 1–23. doi:10.1038/s41392-023-01674-3.
  195. Chow, A., Perica, K., Klebanoff, C. A., and Wolchok, J. D. (2022). Clinical Implications of T Cell Exhaustion for Cancer Immunotherapy, Nature Reviews Clinical Oncology, Vol. 19, No. 12, 775–790. doi:10.1038/s41571-022-00689-z.
  196. Madan, R. A., Antonarakis, E. S., Drake, C. G., Fong, L., Yu, E. Y., McNeel, D. G., Lin, D. W., Chang, N. N., Sheikh, N. A., and Gulley, J. L. (2020). Putting the Pieces Together: Completing the Mechanism of Action Jigsaw for Sipuleucel-T, JNCI: Journal of the National Cancer Institute, Vol. 112, No. 6, 562–573. doi:10.1093/jnci/djaa021.
  197. Madan, R. A., Mohebtash, M., Arlen, P. M., Vergati, M., Rauckhorst, M., Steinberg, S. M., Tsang, K. Y., Poole, D. J., Parnes, H. L., Wright, J. J., Dahut, W. L., Schlom, J., and Gulley, J. L. (2012). Ipilimumab and a Poxviral Vaccine Targeting Prostate-Specific Antigen in Metastatic Castration-Resistant Prostate Cancer: A Phase 1 Dose-Escalation Trial, The Lancet. Oncology, Vol. 13, No. 5, 501–508. doi:10.1016/S1470-2045(12)70006-2.
  198. McNeel, D. G., Eickhoff, J. C., Jeraj, R., Staab, M. J., Straus, J., Rekoske, B., and Liu, G. (2017). DNA Vaccine with Pembrolizumab to Elicit Antitumor Responses in Patients with Metastatic, Castration-Resistant Prostate Cancer (mCRPC)., Journal of Clinical Oncology, Vol. 35, No. 7_suppl, 168–168. doi:10.1200/JCO.2017.35.7_suppl.168.
  199. Antonarakis, E. S., Kibel, A. S., Yu, E. Y., Karsh, L. I., Elfiky, A., Shore, N. D., Vogelzang, N. J., Corman, J. M., Millard, F. E., Maher, J. C., Chang, N. N., DeVries, T., Sheikh, N. A., and Drake, C. G. (2017). Sequencing of Sipuleucel-T and Androgen Deprivation Therapy in Men with Hormone-Sensitive Biochemically Recurrent Prostate Cancer: A Phase II Randomized Trial, Clinical Cancer Research, Vol. 23, No. 10, 2451–2459. doi:10.1158/1078-0432.CCR-16-1780.
  200. Small, E. J., Lance, R. S., Redfern, C. H., Millard, F. E., Gardner, T. A., Karsh, L. I., Dawson, N. A., McCoy, C., Stubbs, A., DeVries, T., Dela Rosa, C. P., Sheikh, N. A., and Shore, N. D. (2013). A Randomized Phase II Trial of Sipuleucel-T with Concurrent or Sequential Abiraterone Acetate (AA) plus Prednisone (P) in Metastatic Castrate-Resistant Prostate Cancer (mCRPC)., Journal of Clinical Oncology, Vol. 31, No. 15_suppl, 5047–5047. doi:10.1200/jco.2013.31.15_suppl.5047.
  201. Podrazil, M., Horvath, R., Becht, E., Rozkova, D., Bilkova, P., Sochorova, K., Hromadkova, H., Kayserova, J., Vavrova, K., Lastovicka, J., Vrabcova, P., Kubackova, K., Gasova, Z., Jarolim, L., Babjuk, M., Spisek, R., Bartunkova, J., and Fucikova, J. (2015). Phase I/II Clinical Trial of Dendritic-Cell Based Immunotherapy (DCVAC/PCa) Combined with Chemotherapy in Patients with Metastatic, Castration-Resistant Prostate Cancer, Oncotarget, Vol. 6, No. 20, 18192–18205. doi:10.18632/oncotarget.4145.
  202. Vogelzang, N. J., Beer, T. M., Gerritsen, W., Oudard, S., Wiechno, P., Kukielka-Budny, B., Samal, V., Hajek, J., Feyerabend, S., Khoo, V., Stenzl, A., Csöszi, T., Filipovic, Z., Goncalves, F., Prokhorov, A., Cheung, E., Hussain, A., Sousa, N., Bahl, A., Hussain, S., Fricke, H., Kadlecova, P., Scheiner, T., Korolkiewicz, R. P., Bartunkova, J., Spisek, R., VIABLE Investigators, Stadler, W., Berg, A. S., Kurth, K.-H., Higano, C. S., Aapro, M., Krainer, M., Hruby, S., Meran, J., Polyakov, S., Machiels, J.-P., Roumeguere, T., Ackaert, K., Lumen, N., Gil, T., Minchev, V., Tomova, A., Dimitrov, B., Koleva, M., Juretic, A., Fröbe, A., Vojnovic, Z., Drabek, M., Jarolim, L., Buchler, T., Kindlova, E., Schraml, J., Zemanova, M., Prausova, J., Melichar, B., Chodacka, M., Jansa, J., Daugaard, G., Delonchamps, N., Duclos, B., Culine, S., Deplanque, G., Le Moulec, S., Hammerer, P., Rodemer, G., Ritter, M., Merseburger, A., Grimm, M.-O., Damjanoski, I., Wirth, M., Burmester, M., Miller, K., Herden, J., Keck, B., Wuelfing, C., Winter, A., Boegemann, M., Von Schmeling, I. K., Fornara, P., Jaeger, E., Bodoky, G., Pápai, Z., Böszörményi-Nagy, G., Vanella, P., SotoParra, H., Passalacqua, R., Ferrau, F., Maio, M., Fratino, L., Cortesi, E., Purkalne, G., Asadauskiene, J., Janciauskiene, R., Tulyte, S., Cesas, A., Polee, M., Haberkorn, B., Van De Eertwegh, F., Van Den Berg, P., Beeker, A., Nieboer, P., Zdrojowy, R., Staroslawska, E., Fijuth, J., Sikora-Kupis, B., Karaszewska, B., Fernandes, I., Sousa, G., Rodrigues, T., Dzamic, Z., Babovic, N., Cvetkovic, B., Sokol, R., Mikuláš, J., Gajdos, M., Brezovsky, M., Mincik, I., Breza, J., Arranz, J. A., Calvo, V., Rubio, G., Chapado, M. S., Boreu, P. G., Montesa, A., Olmos, D., Mellado, B., Castellano, D., Puente, J., Karlsson, E. T., Ahlgren, J., Pandha, H., Mazhar, D., Vilarino-Varela, M., Elliott, T., Pedley, I., Zarkar, A., Law, A., Slater, D., Karlin, G., Bilusic, M., Redfern, C., Gaur, R., McCroskey, R., Clarkson, D., Agrawal, M., Shtivelband, M., Nordquist, L., Karim, N., Hauke, R., Flaig, T., Jhangiani, H., Singal, R., Choi, B., Reyes, E., Corman, J., Hwang, C., Appleman, L., McClay, E., Fleming, M., Gunuganti, V., Cheung, E., Gartrell, B., Sartor, A., Williamson, S., Gandhi, J., Schnadig, I., Burke, J., Bloom, S., Shore, N., Mayer, T., Oh, W., Bryce, A., Belkoff, L., Vaishampayan, U., Agarwala, S., Kucuk, O., Agrawal, A., Walsh, W., Poiesz, B., Harshman, L., Dawson, N., and Sharma, S. (2022). Efficacy and Safety of Autologous Dendritic Cell–Based Immunotherapy, Docetaxel, and Prednisone vs Placebo in Patients With Metastatic Castration-Resistant Prostate Cancer: The VIABLE Phase 3 Randomized Clinical Trial, JAMA Oncology, Vol. 8, No. 4, 546. doi:10.1001/jamaoncol.2021.7298.
  203. Kongsted, P., Borch, T. H., Ellebaek, E., Iversen, T. Z., Andersen, R., Met, Ö., Hansen, M., Lindberg, H., Sengeløv, L., and Svane, I. M. (2017). Dendritic Cell Vaccination in Combination with Docetaxel for Patients with Metastatic Castration-Resistant Prostate Cancer: A Randomized Phase II Study, Cytotherapy, Vol. 19, No. 4, 500–513. doi:10.1016/j.jcyt.2017.01.007.
  204. Li, C., Sun, H., Wei, W., Liu, Q., Wang, Y., Zhang, Y., Lian, F., Liu, F., Li, C., Ying, K., Huo, H., Qi, Z., and Li, B. (2020). Mitoxantrone Triggers Immunogenic Prostate Cancer Cell Death via P53-Dependent PERK Expression, Cellular Oncology (Dordrecht, Netherlands), Vol. 43, No. 6, 1099–1116. doi:10.1007/s13402-020-00544-2.
  205. Zhai, J., Gu, X., Liu, Y., Hu, Y., Jiang, Y., and Zhang, Z. (2023). Chemotherapeutic and Targeted Drugs-Induced Immunogenic Cell Death in Cancer Models and Antitumor Therapy: An Update Review, Frontiers in Pharmacology, Vol. 14. doi:10.3389/fphar.2023.1152934.
  206. Garnett-Benson, C., Hodge, J. W., and Gameiro, S. R. (2015). Combination Regimens of Radiation Therapy and Therapeutic Cancer Vaccines: Mechanisms and Opportunities, Seminars in Radiation Oncology, Vol. 25, No. 1, 46–53. doi:10.1016/j.semradonc.2014.07.002.
  207. Cadena, A., Cushman, T., Anderson, C., Barsoumian, H., Welsh, J., and Cortez, M. (2018). Radiation and Anti-Cancer Vaccines: A Winning Combination, Vaccines, Vol. 6, No. 1, 9. doi:10.3390/vaccines6010009.
  208. Gulley, J. L., Arlen, P. M., Bastian, A., Morin, S., Marte, J., Beetham, P., Tsang, K.-Y., Yokokawa, J., Hodge, J. W., Ménard, C., Camphausen, K., Coleman, C. N., Sullivan, F., Steinberg, S. M., Schlom, J., and Dahut, W. (2005). Combining a Recombinant Cancer Vaccine with Standard Definitive Radiotherapy in Patients with Localized Prostate Cancer, Clinical Cancer Research, Vol. 11, No. 9, 3353–3362. doi:10.1158/1078-0432.CCR-04-2062.
  209. Mondini, M., Nizard, M., Tran, T., Mauge, L., Loi, M., Clémenson, C., Dugue, D., Maroun, P., Louvet, E., Adam, J., Badoual, C., Helley, D., Dransart, E., Johannes, L., Vozenin, M.-C., Perfettini, J.-L., Tartour, E., and Deutsch, E. (2015). Synergy of Radiotherapy and a Cancer Vaccine for the Treatment of HPV-Associated Head and Neck Cancer, Molecular Cancer Therapeutics, Vol. 14, No. 6, 1336–1345. doi:10.1158/1535-7163.MCT-14-1015.
  210. Korbelik, M. (2022). Radiovaccination Strategy for Cancer Treatment Integrating Photodynamic Therapy-Generated Vaccines with Radiotherapy, International Journal of Molecular Sciences, Vol. 23, No. 20, 12263. doi:10.3390/ijms232012263.
  211. Krzyszczyk, P., Acevedo, A., Davidoff, E. J., Timmins, L. M., Marrero-Berrios, I., Patel, M., White, C., Lowe, C., Sherba, J. J., Hartmanshenn, C., O’Neill, K. M., Balter, M. L., Fritz, Z. R., Androulakis, I. P., Schloss, R. S., and Yarmush, M. L. (2018). The Growing Role of Precision and Personalized Medicine for Cancer Treatment, Technology, Vol. 6, Nos. 3–4, 79–100. doi:10.1142/S2339547818300020.
  212. Anassi, E., and Ndefo, U. A. (2011). Sipuleucel-T (Provenge) Injection, Pharmacy and Therapeutics, Vol. 36, No. 4, 197–202.
  213. Jönsson, B., and Wilking, N. (2012). Cancer Vaccines and Immunotherapeutics, Human Vaccines & Immunotherapeutics, Vol. 8, No. 9, 1360–1363. doi:10.4161/hv.21921.
  214. Lorgelly, P., Pollard, J., Cubi-Molla, P., Cole, A., Sim, D., and Sussex, J. (2020). Outcome-Based Payment Schemes: What Outcomes Do Patients with Cancer Value?, The Patient, Vol. 13, No. 5, 599–610. doi:10.1007/s40271-020-00430-x.
  215. Kwilas, A. R., Gameiro, S. R., Kim, P. S., Malamas, A. S., and Hodge, J. W. (2015). Improving Clinical Benefit for Prostate Cancer Patients through the Combination of Androgen Deprivation and Immunotherapy, Oncoimmunology, Vol. 4, No. 6, e1009303. doi:10.1080/2162402X.2015.1009303.
  216. Yang, C., Jin, J., Yang, Y., Sun, H., Wu, L., Shen, M., Hong, X., Li, W., Lu, L., Cao, D., Wang, X., Sun, J., Ye, Y., Su, B., and Deng, L. (2022). Androgen Receptor-Mediated CD8+ T Cell Stemness Programs Drive Sex Differences in Antitumor Immunity, Immunity, Vol. 55, No. 7, 1268-1283.e9. doi:10.1016/j.immuni.2022.05.012.
  217. Muralidhar, A., Gamat-Huber, M., Vakkalanka, S., and McNeel, D. G. (2024). Sequence of Androgen Receptor-Targeted Vaccination with Androgen Deprivation Therapy Affects Anti-Prostate Tumor Efficacy, Journal for ImmunoTherapy of Cancer, Vol. 12, No. 5, e008848. doi:10.1136/jitc-2024-008848.
  218. Long, X., Hou, H., Wang, X., Liu, S., Diao, T., Lai, S., Hu, M., Zhang, S., Liu, M., and Zhang, H. (2020). Immune Signature Driven by ADT-Induced Immune Microenvironment Remodeling in Prostate Cancer Is Correlated with Recurrence-Free Survival and Immune Infiltration, Cell Death & Disease, Vol. 11, No. 9, 779. doi:10.1038/s41419-020-02973-1.
  219. Deng, Z., Tian, Y., Song, J., An, G., and Yang, P. (2022). mRNA Vaccines: The Dawn of a New Era of Cancer Immunotherapy, Frontiers in Immunology, Vol. 13, 887125. doi:10.3389/fimmu.2022.887125.
  220. Colluru, V. T., Johnson, L. E., Olson, B. M., and McNeel, D. G. (2016). Preclinical and Clinical Development of DNA Vaccines for Prostate Cancer, Urologic Oncology, Vol. 34, No. 4, 193–204. doi:10.1016/j.urolonc.2013.09.014.
  221. Sardesai, N. Y., and Weiner, D. B. (2011). Electroporation Delivery of DNA Vaccines: Prospects for Success, Current Opinion in Immunology, Vol. 23, No. 3, 421–429. doi:10.1016/j.coi.2011.03.008.
  222. Kisakov, D. N., Belyakov, I. M., Kisakova, L. A., Yakovlev, V. A., Tigeeva, E. V., and Karpenko, L. I. (2024). The Use of Electroporation to Deliver DNA-Based Vaccines, Expert Review of Vaccines, Vol. 23, No. 1, 102–123. doi:10.1080/14760584.2023.2292772.
  223. Shah, K., Ganapathy, A., Borkowski, A., Shah, N., Bansal, D., Beck, R., Knoche, E. M., Picus, J., Reimers, M. A., Roth, B. J., Gulley, J. L., Schreiber, R., and Pachynski, R. K. (2022). A Pilot Trial of Neoantigen DNA Vaccine in Combination with Nivolumab/Ipilimumab and Prostvac in Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)., Journal of Clinical Oncology, Vol. 40, No. 16_suppl, 5068–5068. doi:10.1200/JCO.2022.40.16_suppl.5068.
  224. O’Cathail, S. M., Pokrovska, T. D., Maughan, T. S., Fisher, K. D., Seymour, L. W., and Hawkins, M. A. (2017). Combining Oncolytic Adenovirus with Radiation—A Paradigm for the Future of Radiosensitization, Frontiers in Oncology, Vol. 7, 153. doi:10.3389/fonc.2017.00153.
  225. Dias, J. D., Hemminki, O., Diaconu, I., Hirvinen, M., Bonetti, A., Guse, K., Escutenaire, S., Kanerva, A., Pesonen, S., Löskog, A., Cerullo, V., and Hemminki, A. (2012). Targeted Cancer Immunotherapy with Oncolytic Adenovirus Coding for a Fully Human Monoclonal Antibody Specific for CTLA-4, Gene Therapy, Vol. 19, No. 10, 988–998. doi:10.1038/gt.20

Downloads

Published

2025-03-19

How to Cite

Runtunuwu, S. V. B. E., Tallei, T. E. and Turalaki, G. L. A. (2025) “Prostate Cancer Vaccines: Progress, Challenges, and Future Directions”, Heca Journal of Applied Sciences, 3(1), pp. 30–55. doi: 10.60084/hjas.v3i1.263.

Issue

Vol. 3 No. 1 (2025): March 2025

Section

Articles

License

Copyright (c) 2025 Stefanus Vicky Bernhard Elisa Runtunuwu, Trina Ekawati Tallei, Grace Lendawati Amelia Turalaki

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.